glp 1 agonism GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders Mechanisms of action of GLP-1RA.

Description

If patients are not monitored, these issues can hide behind the headline of successful weight loss. No Standard Nutrition Monitoring Framework Exists for GLP-1 Drugs Currently no consensus guidelines for micronutrient monitoring in patients receiving GLP-1 receptor agonists are in place

Data are more controversial in type-2 diabetes and although first reports did not find evidence of protective effects of the GLP-1 receptor agonist on bone fracture [872,873], more recent data suggest that liraglutide and lixisenatide, but not exenatide, contribute to reduce fractures in the diabetic population [874]

Patients typically experience reductions in HbA1c (glycated haemoglobin) of approximately 1.01.5% (1116 mmol/mol) when added to existing therapy, with some agents achieving even greater reductions

3.1 Tirzepatide effects: glucose lowering effects of tirzepatide Tirzepatide, a once-weekly subcutaneous injection, was FDA approved in May 2022 as an adjunct treatment with diet and exercise to improve glycemic control in adults with Type 2 diabetes [43]